Abbvie Inc ABBV

$294.45 -0.53 (-0.18%)

Valuation

Market cap
521,411,360,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
22.91
P/E (forward)
21.02
Profit margin
6.91%
Debt to equity
-17.83

Trading

Volume
4,826,816
Avg volume
4,944,142
Day's range
$294.07 – $300.42
Shares out
1,767,616,000
Stochastic %K
61%
Beta
0.20
Analysts
Moderate Buy
Price target
$306.93

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

openclassaction2 Nov 13, 6:53 AM
$ABBV a suit alleges abbvie failed to warn juvederm fillers can cause delayed granulomas, per open class actions. lawsuit stage, nothing to claim. seems like warnings matter
0 replies
55X_ROI_Q1_2026 Nov 13, 12:47 AM
$SLS $ABBV SLS is about to Announce Phase 3 Registrational Trial results that will give it the FDA GREEN LIGHT TO A $28B TOTAL ADDRESSABLE MARKET I told Everyone Here Earlier Today -- repeatedly -- I've been in this stock since before Methuselah - -- if you want to understand what's going Scroll My Posts - and buy as many as you can nutsack up.
0 replies
55X_ROI_Q1_2026 Nov 13, 12:35 AM
$SLS $ABBV SLS is about to Announce Phase 3 Registrational Trial results that will give it the FDA GREEN LIGHT TO A $28B TOTAL ADDRESSABLE MARKET I told Everyone Here Earlier Today -- repeatedly -- I've been in this stock since before Methuselah - -- if you want to understand what's going Scroll My Posts - and buy as many as you can nutsack up.
0 replies
55X_ROI_Q1_2026 Nov 13, 12:17 AM
$SLS $ABBV $XBI Angelos M. Stergiou Founder, President, CEO & Director I think if I can just chime in for one second, Li, to add on to what Dr. Jamy just said - in our research that we have done in the U.S., EU5 and Japan only, once you funnel through the treatment landscape, that allows for about 10,000 patients or so that would be eligible in the CR2 maintenance phase, And as you know very well, there's nothing approved in CR2 maintenance - remember, we're going after patients in second complete remission, where nothing is approved. Even venetoclax and hypomethylate- as you heard from Dr. Jamy, but also previously from Dr. Levy, it's still in that 6, 7, 8 months' time frame. So more and more drugs have gotten patients into remission. Unfortunately, those ineligible or unable to get transplanted just don't do well, and that's where we hope GPS will make a significant impact. //
0 replies
55X_ROI_Q1_2026 Nov 12, 11:46 PM
$SLS $ABBV $XBI
0 replies
55X_ROI_Q1_2026 Nov 12, 10:31 PM
$SLS $ABBV Mark this POST What is GPS WORTH? That is the question the Market will Now Seriously be Considering. $MRNA • Just the initial 12,500 Patient CR2/3 AML Market equates to $6.25B Total Addressable Market 12,500 * $500K Rev Per Patient - $300K Rev Y1 + $120K Y2 + $80K Y3+ $6.25B in Potential Revenue - worth $25B to BP $120 Per Share and Gps will Set record patient uptake rates, due to the Ease of administration, pristine safety and 3x OS advantage - Gps Phase 3 MOS is right now at Least > 34 Months LONGER THAN Standard of Care ORAL Az in CR1... another 50,000 AML Patients each year in CR1 + 100,000 AML Patients currently in Remission who'll immediately benefit for GPS immunotherapy preventing relapse. //
1 replies
55X_ROI_Q1_2026 Nov 12, 9:20 PM
$SLS $ABBV What is GPS WORTH? That is the question the Market will Now Seriously be Considering. $MRNA • Just the initial 12,500 Patient CR2/3 AML Market equates to $6.25B Total Addressable Market 12,500 * $500K Rev Per Patient - $300K Rev Y1 + $120K Y2 + $80K Y3+ $6.25B in Potential Revenue - worth $25B to BP $120 Per Share and Gps will Set record patient uptake rates, due to the Ease of administration, pristine safety and 3x OS advantage - Gps Phase 3 MOS is right now at Least > 34 Months LONGER THAN Standard of Care ORAL Az in CR1... another 50,000 AML Patients each year in CR1 + 100,000 AML Patients currently in Remission who'll immediately benefit for GPS immunotherapy preventing relapse.
0 replies
55X_ROI_Q1_2026 Nov 12, 9:13 PM
$SLS $ABBV $XBI 2 Fda Green Light Trial Readouts This Quarter - Each worth Many Times the current manipulated Share PRice. This is COMPLETE ENROLLMENT in Front Line SLS009/TAMBICICLIB Cohort - AML-MR P2 Expansion Trial Data requested by the FDA for Accelerated Approval. -- 40 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Preliminary Topline Data Expected in Q4 2026 -
1 replies